Ftse Mib
36.200,72
0,24%
DAX
21.394,93
-0,11%
S&P 500
6.101,24
-0,29%
NASDAQ
19.954,30
-0,50%
Bitcoin
104.640,44
-0,20%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Precision BioSciences Inc (DTIL) Precision BioSciences Inc (DTIL) Notizie

DTIL

Precision BioSciences (DTIL)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DTIL
DataOraFonteTitoloSimboloCompagnia
24/01/202521:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
23/01/202503:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
09/01/202516:01Business WirePrecision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) DeficiencyNASDAQ:DTILPrecision BioSciences Inc
09/01/202514:00Business WireiECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) DeficiencyNASDAQ:DTILPrecision BioSciences Inc
08/01/202514:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DTILPrecision BioSciences Inc
18/12/202413:01Business WirePrecision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis BNASDAQ:DTILPrecision BioSciences Inc
21/11/202413:01Business WirePrecision BioSciences to Participate in Upcoming November Investor ConferencesNASDAQ:DTILPrecision BioSciences Inc
15/11/202413:00Business WirePrecision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis BNASDAQ:DTILPrecision BioSciences Inc
04/11/202413:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DTILPrecision BioSciences Inc
04/11/202413:01Business WirePrecision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:DTILPrecision BioSciences Inc
29/10/202412:01Business WirePrecision BioSciences to Report Third Quarter Results on November 4, 2024NASDAQ:DTILPrecision BioSciences Inc
28/10/202412:01Business WirePrecision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024NASDAQ:DTILPrecision BioSciences Inc
24/10/202422:15Business WirePrecision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual CongressNASDAQ:DTILPrecision BioSciences Inc
24/10/202414:47Business WirePrecision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis BNASDAQ:DTILPrecision BioSciences Inc
21/10/202413:01Business WirePrecision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare ConferencesNASDAQ:DTILPrecision BioSciences Inc
16/10/202413:01Business WirePrecision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual CongressNASDAQ:DTILPrecision BioSciences Inc
03/10/202413:01Business WirePrecision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual ConferenceNASDAQ:DTILPrecision BioSciences Inc
30/09/202413:01Business WirePrecision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis BNASDAQ:DTILPrecision BioSciences Inc
20/09/202413:01Business WirePrecision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:DTILPrecision BioSciences Inc
12/09/202413:15Business WirePrecision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical ExecutionNASDAQ:DTILPrecision BioSciences Inc
04/09/202413:01Business WirePrecision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare ConferenceNASDAQ:DTILPrecision BioSciences Inc
03/09/202413:01Business WirePrecision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel DealNASDAQ:DTILPrecision BioSciences Inc
09/08/202413:01Business WirePrecision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple SclerosisNASDAQ:DTILPrecision BioSciences Inc
01/08/202413:15Business WirePrecision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:DTILPrecision BioSciences Inc
31/07/202413:01Business WirePrecision BioSciences to Participate in Upcoming August Investor ConferencesNASDAQ:DTILPrecision BioSciences Inc
29/07/202422:15Business WirePrecision BioSciences to Report Second Quarter Results on August 1, 2024NASDAQ:DTILPrecision BioSciences Inc
08/07/202413:01Business WirePrecision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside SummitNASDAQ:DTILPrecision BioSciences Inc
01/07/202413:01Business WirePrecision BioSciences Announces its Addition to the Russell Microcap® IndexNASDAQ:DTILPrecision BioSciences Inc
27/06/202413:01Business WirePrecision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025NASDAQ:DTILPrecision BioSciences Inc
20/06/202413:00Business WirePrecision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical ReadinessNASDAQ:DTILPrecision BioSciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DTIL

La tua Cronologia

BIT
BMPS
Banca Monte Dei Paschi D...
BIT
UCG
Unicredit
BIT
MB
Mediobanca Banca di Cred...
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
CPR
Davide Campari
BIT
BAMI
Banco BPM
BIT
MONC
Moncler
BIT
SPM
Saipem
BIT
STMMI
ST Microelectronics
BIT
BPE
Bper Banca
BIT
RACE
Ferrari NV
BIT
IVG
Iveco Group NV
BIT
G
Generali
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network